This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Metronidazole in Crohn's disease and ulcerative colitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • antibacterials, such as metronidazole and ciprofloxacin, may be prescribed in the treatment of fistulating Crohn's Disease to treat accompanying abscesses or in perianal Crohn's Disease or sepsis (1)
  • antibiotics, including metronidazole, are indicated in
    • the treatment of symptoms attributable bacterial overgrowth
    • septic complications
    • perineal disease (3)
  • significant side-effects of metronidazole include peripheral neuropathy if used long term (over three months), a bad taste in the mouth and a disulfiram-like interaction with alcohol

  • antibiotics such as ciprofloxacin have also been used in the place of steroids to treat moderate relapses of ulcerative colitis

NICE suggest (4):

  • to maintain remission in people with ileocolonic Crohn's disease who have had complete macroscopic resection within the last 3 months, consider azathioprine in combination with up to 3 months' postoperative metronidazole

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.